CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Iovance's Lifileucel Shows 50% Response Rate in Soft Tissue Sarcoma Pilot Trial

By Public Technologies
  • Iovance Biotherapeutics announced pilot trial results showing durable responses to lifileucel in advanced soft tissue sarcomas, presented at ESMO 2026.
  • Tumor shrinkage occurred in refractory undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma; all responses remained ongoing at the September 9, 2026, cutoff.
  • The safety profile was consistent with the lifileucel treatment regimen in other indications.
  • The FDA granted lifileucel fast track designation for both cancers in the second quarter of 2026.
  • Enrollment is underway in the SARATOGA registrational study to support potential approvals in both cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852689) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk